Summary
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin's disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin's lymphoma (NHL). The world prevalence is approximately 650,000 cases, of which 300,000 are low grade and 350,000 are aggressive. The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide thru this field and bring structure and knowledge enable our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.
Research and analysis highlights
At the American Society of Clinical Oncology 2005 meeting new investigations showed that freedom from treatment failure was significantly better for patients with Hodgkin's disease undergoing transplantation compared to non-transplant salvage, regardless of whether they relapse early or late following primary chemotherapy. Rituximab has been heavily investigated in a variety of treatment regimes. Published trial data show an increase in response rates when rituximab is combined with current chemotherapy regimens in both the first- and second- line settings. In addition, rituximab show significant off-label usage. Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
Scope of this report
Thorough examination of status and impact of several novel drugs in development
Discussion of the challenges in current treatment strategies.
Company profiles and their anticancer pipeline of most companies in the field
Key reasons to read this report
Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in lymphoma R&D, and the results of clinical trials to date.
Gain insight into the current challenges and commercial opportunities associated with lymphoma therapy
Some of the drugs included in this analysis:
Aldesleukin , Apolizumab, Arsenic trioxide, Bevacizumab, BiovaxID , Bortezomib , CMC-544 , Enzastaurin , Epratuzumab, FavId , Flavopiridol, Genasense , IDEC-114 , Marqibo, MyVax, Nelarabine , Pixantrone , SGN-30, SGN-40 , Temsirolimus , Zanolimumab.
Some of the companies included in this analysis:
Accentia BioPharmaceuticals, Biogen , Cell Therapeutics , Cephalon , Chiron (now Novartis) Corporation , Eli Lilly , Favrille , Genentech , Genitope , Genmab , Genta , GlaxoSmithKline, Immunomedics , Inex Pharmaceuticals , Millennium Pharmaceuticals, Protein Design Labs , Roche, Sanofi-Aventis, Seattle Genetics , Wyeth.
|
